4D Molecular Therapeutics, Inc. FDMT
12.28 USD +0.33 (+2.76%)
At closeNov 4, 2026, 4:39 PM EST
12.28 0.00 0.00%
After hours · Nov 4, 4:39 PM ET
11.55 Day range 12.42
6.96 52-week range 16.93
- YTD
- +63.73%
- 1 year
- +14.23%
News
globenewswire.com 4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
zacks.com 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
marketbeat.com 4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy 4D Molecular Therapeutics NASDAQ: FDMT used its first Investor Day to outline its development and commercial plans for 4D-150, an investigational intravitreal gene therapy for wet age-related macular…
benzinga.com HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.
seekingalpha.com 4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript 4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript
defenseworld.net Reviewing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT) GeoVax Labs (NASDAQ: GOVX - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast…
benzinga.com General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were mixed as GM shares fell 7.3% despite an earnings beat; FreightCar America, 4D Molecular and others also declined premarket.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
globenewswire.com 4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
defenseworld.net 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) has received an average rating of "Moderate Buy" from the twelve brokerages that are covering the company, MarketBeat Ratings reports.…
benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25 Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.
globenewswire.com 4DMT to Host Investor Day on October 21, 2026 Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.
seekingalpha.com 4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway 4D Molecular Therapeutics remains a 'Buy' as its gene therapy 4D-150 advances in phase 3 trials for wet AMD and diabetic macular edema [DME]. Topline data from the pivotal 4FRONT-1 and 4FRONT-2 wet…
benzinga.com B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33 B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
globenewswire.com 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
benzinga.com Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
defenseworld.net Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an…
defenseworld.net 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock,…
seekingalpha.com 4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript 4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
seekingalpha.com 4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday Analysts upgraded Coinbase, 4D Molecular Therapeutics, Affirm, Chime Financial and Bullish, raising ratings and price targets.- benzinga.com Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.
globenewswire.com 4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
globenewswire.com 4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
defenseworld.net 4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 17.0% during the first quarter, according to its most recent filing with the Securities and…
defenseworld.net Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission…
defenseworld.net 4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy? 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s share price reached a new 52-week high on Tuesday. The company traded as high as $15.03 and last traded at $14.55, with a volume of…
globenewswire.com 4DMT Announces New Employment Inducement Grants EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…
benzinga.com B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37 B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.
benzinga.com 4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win 4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
benzinga.com HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.- benzinga.com Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well…
- benzinga.com 4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration 4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting…
benzinga.com 4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.99) by 2.02 percent. This is a 17.44 percent decrease over…
benzinga.com HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.- benzinga.com RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35 RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.
- benzinga.com UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $(0.53) by 181.13 percent. This is a 147.78 percent increase over…
- benzinga.com 4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment…
benzinga.com Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) 
benzinga.com BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $26 price target.
- benzinga.com 4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung Disease Shows Meaningful Lung Function Activity Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic…
- benzinga.com RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $32 RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $26 to $32.
- benzinga.com Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33 Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight and lowers the price target from $38 to $33.
- benzinga.com Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $26 Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $25 to $26.
- benzinga.com 4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Estimate 4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.98) by 3.27 percent. This is a 27.85 percent decrease over…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 4D Molecular Therapeutics Prices $100M Offering Including 8.4M Common Shares At $10.51 Each And 1.1M Pre-Funded Warrants At $10.5099 Each 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment…- benzinga.com 4DMT's 4D-150 Demonstrates Durable, Multi-Year Benefit Supporting Its Potential As A Backbone Therapy For Wet AMD And Retinal Diseases 4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all…
- benzinga.com Reported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In Milestones To Develop And Commercialize 4D-150 Across Asia-Pacific 4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global…